<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isavuconazole (isavuconazonium sulfate): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isavuconazole (isavuconazonium sulfate): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isavuconazole (isavuconazonium sulfate): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="100324" href="/d/html/100324.html" rel="external">see "Isavuconazole (isavuconazonium sulfate): Drug information"</a> and <a class="drug drug_patient" data-topicid="100614" href="/d/html/100614.html" rel="external">see "Isavuconazole (isavuconazonium sulfate): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27657948"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cresemba</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53275618"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cresemba</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28334634"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Azole Derivative</span>;</li>
<li>
<span class="list-set-name">Antifungal Agent, Oral</span>;</li>
<li>
<span class="list-set-name">Antifungal Agent, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F56934278"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage expressed as milligrams of <b>isavuconazonium sulfate</b>; 372 mg isavuconazonium sulfate = 200 mg isavuconazole. Dosing is presented as weight-directed doses (mg isavuconazonium sulfate/<b>kg</b>) and fixed doses (mg isavuconazonium sulfate); use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Switching between the IV and oral formulations of isavuconazonium sulfate is acceptable; the same dose and frequency can be used; additional loading doses are NOT necessary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive:</b>
<b>Note: </b>Minimum duration of therapy is 6 to 12 weeks; duration should be individualized depending on degree and duration of immunosuppression, disease site, and evidence of improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intravenous:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;3 years: Initial (loading doses): IV: 15 mg isavuconazonium sulfate/<b>kg</b>/dose every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 15 mg isavuconazonium sulfate/<b>kg</b>/dose every 24 hours; maximum dose: 372 mg isavuconazonium sulfate/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents &lt;18 years: IV: Initial (loading doses): 10 mg isavuconazonium sulfate/<b>kg</b>/dose every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last dosing dose): 10 mg isavuconazonium sulfate/<b>kg</b>/dose every 24 hours; maximum dose: 372 mg isavuconazonium sulfate/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">16 to &lt;18 kg: Oral: Initial (loading doses): 149 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 149 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">18 to &lt;25 kg: Oral: Initial (loading doses): 223.5 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 223.5 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;32 kg: Oral: Initial (loading doses): 298 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 298 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥32 kg: Oral: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: Oral: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2bd63e09-635f-4b3b-ac73-b3f4a49de4b5">Candidiasis, esophageal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, esophageal (alternative agent):</b> Limited data available: Multiple regimens reported: Patients with HIV: Adolescents: Oral: 744 mg isavuconazonium sulfate as a single dose, followed by 186 mg isavuconazonium sulfate every 24 hours <b>or</b> 372 mg isavuconazonium sulfate as a single dose, followed by 93 mg isavuconazonium sulfate every 24 hours <b>or</b> 744 mg isavuconazonium sulfate once weekly; treat for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6cb02bb-5399-4d63-aff5-c4b202170424">Mucormycosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive: Note: </b>Treatment duration is highly individualized depending on degree and duration of immunosuppression, disease site, clinical resolution, and improvement on imaging studies; typically weeks to months or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intravenous:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;3 years: Initial (loading doses): IV: 15 mg isavuconazonium sulfate/<b>kg</b>/dose every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 15 mg isavuconazonium sulfate/<b>kg</b>/dose every 24 hours; maximum dose: 372 mg isavuconazonium sulfate/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents &lt;18 years: IV: Initial (loading doses): 10 mg isavuconazonium sulfate/<b>kg</b>/dose every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last dosing dose): 10 mg isavuconazonium sulfate/<b>kg</b>/dose every 24 hours; maximum dose: 372 mg isavuconazonium sulfate/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">16 to &lt;18 kg: Oral: Initial (loading doses): 149 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 149 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">18 to &lt;25 kg: Oral: Initial (loading doses): 223.5 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 223.5 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;32 kg: Oral: Initial (loading doses): 298 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 298 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥32 kg: Oral: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: Oral: Initial (loading doses): 372 mg isavuconazonium sulfate every 8 hours for 6 doses; maintenance (begin 12 to 24 hours after last loading dose): 372 mg isavuconazonium sulfate every 24 hours.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56934279"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children and Adolescents: No dosage adjustment necessary in any degree of kidney impairment; less than 1% is eliminated by the kidney.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Children and Adolescents: Not readily dialyzable; no dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F56934280"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use only when benefits outweigh risks; monitor closely.</p></div>
<div class="block doa drugH1Div" id="F27749198"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="100324" href="/d/html/100324.html" rel="external">see "Isavuconazole (isavuconazonium sulfate): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage expressed as milligrams of isavuconazonium sulfate; switching between the IV and oral formulations of isavuconazonium sulfate is acceptable; for maintenance dosing, it is not necessary to restart dosing with the initial dose regimen when switching between formulations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral: </b>Initial: 372 mg (isavuconazole 200 mg) every 8 hours for 6 doses; Maintenance: 372 mg (isavuconazole 200 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26684607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26684607'])">Ref</a></span>). Start maintenance dose 12 to 24 hours after the last loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy: </i>Minimum of 6 to 12 weeks, although duration is highly dependent on degree/duration of immunosuppression, disease site, and evidence of disease improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Esophageal, fluconazole-refractory disease (alternative agent) (off-label use): Oral:</b> 744 mg (isavuconazole 400 mg) as a single dose, then 186 mg (isavuconazole 100 mg) once daily for 14 to 28 days <b>or</b> 744 mg (isavuconazole 400 mg) once weekly for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1','lexi-content-ref-25561337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1','lexi-content-ref-25561337'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6cb02bb-5399-4d63-aff5-c4b202170424">Mucormycosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive: IV, Oral:</b> Initial: 372 mg (isavuconazole 200 mg) every 8 hours for 6 doses; Maintenance: 372 mg (isavuconazole 200 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26969258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26969258'])">Ref</a></span>). Start maintenance dose 12 to 24 hours after the last loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c68abc8a-b79f-4368-a4bf-6161f16dfcf1">Prophylaxis against invasive fungal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis against invasive fungal infections (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematology malignancy or hematopoietic cell transplant:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> Initial: 372 mg (isavuconazole 200 mg) every 8 hours for 6 doses; Maintenance: 372 mg (isavuconazole 200 mg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34036319','lexi-content-ref-32236406','lexi-content-ref-30958538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34036319','lexi-content-ref-32236406','lexi-content-ref-30958538'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Varies based on degree and duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34036319','lexi-content-ref-32236406','lexi-content-ref-30958538','lexi-content-ref-30179565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34036319','lexi-content-ref-32236406','lexi-content-ref-30958538','lexi-content-ref-30179565'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990897"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27185799','lexi-content-ref-29725999','lexi-content-ref-28271239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27185799','lexi-content-ref-29725999','lexi-content-ref-28271239'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28271239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28271239'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Not significantly dialyzable given high degree of protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31527035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31527035'])">Ref</a></span>). No initial dosage adjustment necessary; however, lower (and sometimes subtherapeutic) concentrations have been reported in critically ill patients receiving renal replacement therapy; monitor patient closely and utilize therapeutic drug monitoring if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36836325','lexi-content-ref-32580296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36836325','lexi-content-ref-32580296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Not significantly dialyzable given high degree of protein binding. No initial dosage adjustment necessary; however, potential adsorption to PIRRT equipment has been reported; monitor patient closely and utilize therapeutic drug monitoring if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427296'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988132"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C):  There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block adr drugH1Div" id="F27767563"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are reported for adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (children, adolescents, and adults: 8% to 13%), skin rash (children, adolescents, and adults: 9% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, and adults: 17% to 23%), constipation (14%), diarrhea (children, adolescents, and adults: 24% to 26%), nausea (children and adolescents: 13%; adults: 28%), vomiting (children, adolescents, and adults: 21% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (children, adolescents, and adults: 17% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (11%), headache (children, adolescents, and adults: 12% to 17%), insomnia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (&lt;5%), atrial flutter (&lt;5%), bradycardia (&lt;5%), chest pain (9%), ECG changes (reduced QT interval) (&lt;5%), hypotension (8%), palpitations (&lt;5%), premature ventricular contractions (&lt;5%), supraventricular extrasystole (&lt;5%), supraventricular tachycardia (&lt;5%), syncope (&lt;5%), thrombophlebitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;5%), dermatitis (&lt;5%), erythema of skin (&lt;5%), exfoliative dermatitis (&lt;5%), urticaria (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoalbuminemia (&lt;5%), hypoglycemia (&lt;5%), hypomagnesemia (5%), hyponatremia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;5%), cholecystitis (&lt;5%), cholelithiasis (&lt;5%), decreased appetite (9%), dysgeusia (&lt;5%), dyspepsia (6%), gastritis (&lt;5%), gingivitis (&lt;5%), stomatitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (&lt;5%), proteinuria (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (&lt;5%), leukopenia (&lt;5%), pancytopenia (&lt;5%), petechia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (&lt;5%), hepatitis (&lt;5%), hepatomegaly (&lt;5%), increased serum alanine aminotransferase (&gt;3 × ULN: ≤4%; &gt;10 × ULN: ≤1%), increased serum aspartate aminotransferase (&gt;3 × ULN: ≤4%; &gt;10 × ULN: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (8%), chills (&lt;5%), confusion (&lt;5%), delirium (9%), depression (&lt;5%), drowsiness (&lt;5%), encephalopathy (&lt;5%), falling (&lt;5%), hallucination (&lt;5%), hypoesthesia (&lt;5%), malaise (&lt;5%), migraine (&lt;5%), paresthesia (&lt;5%), peripheral neuropathy (&lt;5%), seizure (&lt;5%), stupor (&lt;5%), tremor (&lt;5%), vertigo (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (10%), myositis (&lt;5%), neck pain (&lt;5%), ostealgia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuropathy (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney failure (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory failure (7%), bronchospasm (&lt;5%), tachypnea (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, infusion-related reaction</p></div>
<div class="block coi drugH1Div" id="F27378901"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to isavuconazonium sulfate (eg, isavuconazole) or any component of the formulation; concurrent use of strong CYP3A4 inhibitors (eg, ketoconazole, high-dose ritonavir [400 mg every 12 hours]); concurrent use of strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John’s wort, long-acting barbiturates); familial short QT syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent use of moderate CYP3A4/5 inducers (eg, efavirenz, etravirine).</p></div>
<div class="block war drugH1Div" id="F27749131"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Severe reactions (hepatic failure [including fatalities], hepatitis, and cholestasis) have been reported in patients with serious underlying medical conditions (eg, hematologic malignancy). Other reactions (elevations in AST, ALT, alkaline phosphatase and total bilirubin) have also been reported; these elevations are generally reversible and do not require discontinuation of therapy. Monitor liver function tests at baseline and periodically during therapy. If abnormal liver function tests develop, monitor closely for development of severe hepatic reactions. Discontinue therapy if clinical signs and symptoms of liver disease develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylactic reactions, with fatal outcome, have been reported with isavuconazonium sulfate. Discontinue isavuconazonium sulfate if a patient experiences an anaphylactic reaction. Serious hypersensitivity (eg, anaphylaxis) and severe skin reactions (eg, Stevens-Johnson syndrome) have been reported with other azole antifungal agents. Discontinue if a severe skin reaction occurs. There is no information regarding cross-sensitivity between isavuconazonium sulfate and other azoles. Use with caution in patients with hypersensitivity reactions to other azoles.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and monitor for adverse effects in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug particulates: Following dilution for IV infusion, may form precipitate from the insoluble isavuconazole. Use an infusion set with an in-line filter (pore size 0.2 to 1.2 micron) for IV administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion reactions (eg, hypotension, dizziness, chills, dyspnea, paresthesia and hypoesthesia) have been reported during IV administration. Discontinue the infusion if these reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F59034249"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F27657949"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cresemba: 186 mg (isavuconazole 100 mg), 74.5 mg (isavuconazole 40 mg) [contains disodium edta]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cresemba: 372 mg (isavuconazole 200 mg) (1 ea)</p></div>
<div class="block geq drugH1Div" id="F27657947"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28326122"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cresemba Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">74.5 mg (per each): $54.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">186 mg (per each): $134.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cresemba Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">372 mg (per each): $459.47</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53275619"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cresemba: 186 mg (isavuconazole 100 mg) [contains disodium edta]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cresemba: 372 mg (isavuconazole 200 mg) (1 ea)</p></div>
<div class="block admp drugH1Div" id="F56934282"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over a minimum of 1 hour; must be administered via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron). Flush line with NS or D5W before and after infusion. Do not administer as an IV bolus injection. Do not mix or infuse with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food. The manufacturer recommends swallowing capsules whole and states not to chew, crush, dissolve, or open capsules, and recommends using the parenteral product enterally for patients who cannot swallow capsules. However, oral administration of isavuconazonium sulfate by opening capsules and mixing contents with an acidic beverage or soft food (eg, yogurt) has resulted in comparable isavuconazole concentrations to IV administration and administration of intact capsule formulations. If capsules are opened, consider assessing serum concentrations to ensure absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30522521','lexi-content-ref-31094909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30522521','lexi-content-ref-31094909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Feeding tube administration:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Using parenteral formulation: </i>Administer via nasogastric (NG) tube using an appropriate syringe within 1 hour of reconstitution. Once dose administered, flush NG tube with three 5 mL rinses of water.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Using capsules:</i> Isavuconazonium sulfate administration via enteral feeding tubes (eg, gastrostomy tube, gastrojejunostomy [GJ] tube) has been described; open capsules and mix contents with water, saline, or tube feed formulations (eg, 372 mg isavuconazonium sulfate in 10 mL saline). In some cases, isavuconazole concentrations were found to be comparable to those achieved with IV administration; however, in one pharmacokinetic study, opening capsules resulted in lower concentrations compared to IV administration. The manufacturer recommends against using capsules for feeding tube administration; parenteral formulation is preferred. If capsules opened and administered via enteral tube, assess serum concentrations to ensure absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30636363','lexi-content-ref-37864491','lexi-content-ref-33991386','lexi-content-ref-32710097','lexi-content-ref-33247433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30636363','lexi-content-ref-37864491','lexi-content-ref-33991386','lexi-content-ref-32710097','lexi-content-ref-33247433'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F27749202"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over a minimum of 1 hour; must be administered via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron). Flush line with NS or D5W before and after infusion. Do not administer as an IV bolus injection. Do not mix or infuse with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>NG tube:</b> Administer within 1 hour of reconstitution. Once dose administered, flush nasogastric tube with three 5 mL rinses of water. Do not administer intact capsules through an NG tube.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food. The manufacturer recommends to swallow capsules whole; do not chew, crush, dissolve, or open. Administration of isavuconazonium sulfate by opening capsules and mixing contents with saline or tube feed formulations for administration via enteral feeding tubes has resulted in comparable isavuconazole concentrations to IV administration and intact capsule formulations. If capsules are opened, consider assessing serum concentrations to ensure absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30636363','lexi-content-ref-32710097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30636363','lexi-content-ref-32710097'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F27749177"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at 20°C to 25°C (68°F to 77°F) in the original packaging to protect from moisture; excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Store intact vials at 2°C to 8°C (36°F to 46°F). Following reconstitution of the vial with SWFI, use the solution immediately, or store at 5°C to 25°C (41°F to 77°F) for a maximum of 1 hour prior to NG tube administration or preparation of the admixed solution in NS or D5W. The admixed infusion solution should be kept for not more than 6 hours at (20°C to 25°C [68°F to 77°F]) or 24 hours at 2°C to 8°C (36°F to 46°F) prior to use. Do not freeze. Discard any unused portion.</p></div>
<div class="block usep drugH1Div" id="F53571219"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of invasive aspergillosis; treatment of invasive mucormycosis (All indications: Injection: FDA approved in ages ≥1 year and adults; capsule: FDA approved in ages ≥6 years weighing ≥16 kg and adults). Has also been used for treatment of esophageal candidiasis.</p></div>
<div class="block cyt drugH1Div" id="F27542740"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (moderate), OCT1, OCT2, P-glycoprotein/ABCB1; <b>Induces</b> CYP2B6 (weak)</p></div>
<div class="block dri drugH1Div" id="F27542737"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Astemizole.  Management: Avoid concomitant use of astemizole and moderate CYP3A4 inhibitors whenever possible. If combined, monitor closely for increased astemizole toxicities, especially for QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride.  Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: MATE1/2-K Inhibitors may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enasidenib: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib.  Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erythromycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Everolimus.  Management: Afinitor: For TSC-associated SEGA or TSC-associated seizures reduce everolimus dose 50%. For other Afinitor indications, reduce everolimus dose to 2.5 mg/day, increase to 5 mg/day if tolerated. Zortress: Monitor for increased everolimus concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Avoid use of fexinidazole and moderate CYP3A4 inhibitors when possible. If combined, monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: May decrease the serum concentration of Isavuconazonium Sulfate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Futibatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Isavuconazonium Sulfate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib.  Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Isavuconazonium Sulfate may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, lopinavir/ritonavir may increase isavuconazole serum concentrations. Isavuconazonium Sulfate may decrease the serum concentration of Lopinavir. Management: Consider alternatives to this combination. If coadministered, use caution and monitor for increased isavuconazonium effects and toxicities as well as reduced concentrations and effects of lopinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a moderate CYP3A4 inhibitor. For those stable on mavacamten who are initiating a moderate CYP3A4 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: MATE1/2-K Inhibitors may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Isavuconazonium Sulfate may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib.  Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Isavuconazonium Sulfate may increase the serum concentration of Mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: Isavuconazonium Sulfate may increase the serum concentration of Nirmatrelvir and Ritonavir. Nirmatrelvir and Ritonavir may increase the serum concentration of Isavuconazonium Sulfate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Rivaroxaban.  Management: No action is needed in patients with normal renal function. Do not use this combination in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, St Johns Wort may decrease isavuconazole serum concentrations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: Isavuconazonium Sulfate may increase the serum concentration of VinCRIStine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53917300"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use; patients who could become pregnant should use effective contraception during therapy and for 28 days after the last isavuconazonium sulfate dose.</p></div>
<div class="block pri drugH1Div" id="F27748906"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to isavuconazonium sulfate may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53571220"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions with initial doses. LFTs (eg, AST, ALT, alkaline phosphatase, total bilirubin), SCr, sodium, potassium, calcium at baseline and periodically during therapy. Infusion-related reactions (eg, hypotension, dyspnea, chills, dizziness, paresthesias, hypoesthesia) during IV infusion (Ferdjallah 2021; manufacturer's labeling).</p></div>
<div class="block rerp drugH1Div" id="F56934284"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Routine therapeutic drug monitoring is not recommended because efficacy and toxicity have not been associated with specific serum concentrations. However, serum drug concentrations may be considered in some clinical scenarios (eg, if optimal dosing is uncertain or if there is concern for toxicity, therapeutic failure, or possibility of impaired drug absorption [eg, opening capsules]) (Andes 2018; Arrieta 2021; Decembrino 2020; Garner 2021; McCreary 2020; Ross 2020; SIDP [McCreary 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Timing: </i>Initial trough concentrations may be obtained at steady state, ~5 to 7 days after initiation with a loading dose and ~10 to 14 days without a loading dose (SIDP [McCreary 2023]). Some have suggested waiting until 3 weeks after therapy initiation for steady-state concentrations, and then monitoring every 1 to 2 months based on clinical status of patient (Ferdjallah 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Targets:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Trough concentration: Target not well established; 1 to 5 mg/L (Ashkenazi-Hoffnung 2020; Barg 2018; Cornu 2018; Decembrino 2020; Fernández Ledesma 2023; Gatti 2022; Risum 2021; SIDP [McCreary 2023]). Trough concentrations &gt;4.6 to 5.1 mg/L may be associated with increased risk of gastrointestinal toxicity (SIDP [McCreary 2023]).</p>
<p style="text-indent:-2em;margin-left:6em;">AUC<sub>24</sub> (steady-state): 60 to 233 mg•hour/L was targeted for pharmacokinetic studies; based on exposures observed in adult phase 3 and tolerability studies (Arrieta 2021). Pharmacodynamic target for efficacy based on preclinical data is free drug AUC<sub>24</sub>/MIC &gt;25 to 50 (SIDP [McCreary 2023]).</p></div>
<div class="block pha drugH1Div" id="F27749181"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Isavuconazonium sulfate is a prodrug that is rapidly hydrolyzed in the blood to active isavuconazole. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14-alpha-demethylase. This enzyme is responsible for the conversion of lanosterol to ergosterol. An accumulation of methylated sterol precursors and a depletion of ergosterol within the fungal cell membrane weakens the membrane structure and function.</p></div>
<div class="block phk drugH1Div" id="F27749183"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: Isavuconazole: IV: ~450 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Isavuconazole: &gt;99% (primarily to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Isavuconazonium sulfate (prodrug) is rapidly hydrolyzed in the blood by esterases to active isavuconazole and an inactive cleavage product. Isavuconazole is metabolized by CYP3A4, CYP 3A5, and UGT.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Isavuconazole: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: Isavuconazole: 130 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Isavuconazole:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Children and Adolescents: Median range: 1.07 to 1.08 hours (range: 1.02 to 1.35 hours) (Arrieta 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Median range: 3.98 to 4 hours (range: 1.98 to 8.03 hours) (Arrieta 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged isavuconazole); feces (33% as unchanged isavuconazole) (Townsend 2018).</p></div>
<div class="block phksp drugH1Div" id="F51193255"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Patients with mild and moderate hepatic impairment had 40% and 48% lower isavuconazole Cl values, respectively, compared with healthy subjects, resulting in 64% and 84% increased drug exposure, respectively. In addition, patients with moderate hepatic impairment had 30% lower C<sub>max</sub>, compared with healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939958"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cresemba | Isavufic | Isuvaz</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cresemba</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30636363">
<a name="30636363"></a>Adamsick ML, Elshaboury RH, Gift T, Mansour MK, Kotton CN, Gandhi RG. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: a case report. <i>Transpl Infect Dis</i>. 2019;21(2):e13048. doi:10.1111/tid.13048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/30636363/pubmed" id="30636363" target="_blank">30636363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics (AAP) Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29735569">
<a name="29735569"></a>Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. <i>Antimicrob Agents Chemother</i>. 2018;62(7):e00585-18. doi:10.1128/AAC.00585-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/29735569/pubmed" id="29735569" target="_blank">29735569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34031051">
<a name="34031051"></a>Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. <i>Antimicrob Agents Chemother</i>. 2021;65(8):e0029021. doi:10.1128/AAC.00290-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/34031051/pubmed" id="34031051" target="_blank">34031051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32251256">
<a name="32251256"></a>Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. <i>Pediatr Infect Dis J</i>. 2020;39(8):718-724. doi:10.1097/INF.0000000000002671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32251256/pubmed" id="32251256" target="_blank">32251256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29932282">
<a name="29932282"></a>Barg AA, Malkiel S, Bartuv M, Greenberg G, Toren A, Keller N. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. <i>Pediatr Blood Cancer</i>. 2018;65(10):e27281. doi:10.1002/pbc.27281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/29932282/pubmed" id="29932282" target="_blank">29932282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31527035">
<a name="31527035"></a>Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy. <i>Antimicrob Agents Chemother</i>. 2019;63(12):e01085-19. doi:10.1128/AAC.01085-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/31527035/pubmed" id="31527035" target="_blank">31527035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34036319">
<a name="34036319"></a>Bogler Y, Stern A, Su Y, et al. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. <i>Med Mycol</i>. 2021;59(10):970-979. doi:10.1093/mmy/myab025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/34036319/pubmed" id="34036319" target="_blank">34036319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32236406">
<a name="32236406"></a>Bose P, McCue D, Wurster S, et al. Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study.<i> Clin Infect Dis</i>. 2021;72(10):1755-1763. doi:10.1093/cid/ciaa358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32236406/pubmed" id="32236406" target="_blank">32236406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37864491">
<a name="37864491"></a>Bury D, Wolfs TFW, Ter Heine R, et al. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. <i>J Antimicrob Chemother</i>. 2023;78(12):2886-2889. doi:10.1093/jac/dkad324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/37864491/pubmed" id="37864491" target="_blank">37864491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated May 26, 2020. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699664">
<a name="31699664"></a>Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology (ECMM) in cooperation with the Mycoses Study Group Education and Research Consortium (MSG-ERC). <i>Lancet Infect Dis</i>. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/31699664/pubmed" id="31699664" target="_blank">31699664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25624327">
<a name="25624327"></a>Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. <i>Antimicrob Agents Chemother</i>. 2015 Apr;59(4):2078-2085.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/25624327/pubmed" id="25624327" target="_blank">25624327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522521">
<a name="30522521"></a>Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. <i>BMC Pharmacol Toxicol</i>. 2018;19(1):81. doi:10.1186/s40360-018-0273-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/30522521/pubmed" id="30522521" target="_blank">30522521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cresemba.1">
<a name="Cresemba.1"></a>Cresemba (isavuconazonium) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cresemba.2">
<a name="Cresemba.2"></a>Cresemba (isavuconazonium) [product monograph]. Blainville, Quebec, Canada: Avir Pharma Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923872">
<a name="28923872"></a>Desai AV, Kovanda LL, Hope WW, et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. <i>Antimicrob Agents Chemother</i>. 2017;61(12):e01034-17. doi:10.1128/AAC.01034-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/28923872/pubmed" id="28923872" target="_blank">28923872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871077">
<a name="31871077"></a>Decembrino N, Perruccio K, Zecca M, et al. A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. <i>Antimicrob Agents Chemother</i>. 2020;64(3):e01783-19. doi:10.1128/AAC.01783-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/31871077/pubmed" id="31871077" target="_blank">31871077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31094909">
<a name="31094909"></a>De Leonardis F, Novielli C, Giannico B, Mariggiò MA, Castagnola E, Santoro N. Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature. <i>J Pediatr Hematol Oncol</i>. 2020;42(6):e469-e471. doi:10.1097/MPH.0000000000001508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/31094909/pubmed" id="31094909" target="_blank">31094909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24187505">
<a name="24187505"></a>Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. <i>Infect Drug Resist</i>. 2013;6:163-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/24187505/pubmed" id="24187505" target="_blank">24187505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34790078">
<a name="34790078"></a>Ferdjallah A, Nelson KM, Meyer K, Jennissen CA, Ebens CL. Isavuconazonium sulfate use in multi-modal management of invasive mucormycosis in four pediatric allogeneic hematopoietic cell transplant patients. <i>J Pediatr Pharmacol Ther</i>. 2021;26(8):863-867. doi:10.5863/1551-6776-26.8.863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/34790078/pubmed" id="34790078" target="_blank">34790078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37962334">
<a name="37962334"></a>Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, et al. Isavuconazole use and TDM in real-world pediatric practice. <i>Antimicrob Agents Chemother</i>. 2023;67(12):e0082923. doi:10.1128/aac.00829-23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/37962334/pubmed" id="37962334" target="_blank">37962334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30958538">
<a name="30958538"></a>Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. <i>Clin Infect Dis</i>. 2020;70(5):723-730. doi:10.1093/cid/ciz282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/30958538/pubmed" id="30958538" target="_blank">30958538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33991386">
<a name="33991386"></a>Garner LM, Echols CD, Wilson WS. Enteral tube administration of isavuconazole in a pediatric patient. <i>Pediatr Blood Cancer</i>. 2021;68(9):e29108. doi:10.1002/pbc.29108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/33991386/pubmed" id="33991386" target="_blank">33991386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344524">
<a name="35344524"></a>Gatti M, Campoli C, Belotti T, et al. Real-world comparison of isavuconazole and voriconazole in terms of the need for dosage adjustments guided by clinical pharmacological advice during primary prophylaxis of invasive fungal infections in pediatric patients with hemato-oncological malignancies. <i>Ther Drug Monit</i>. 2022;44(5):641-650. doi:10.1097/FTD.0000000000000980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/35344524/pubmed" id="35344524" target="_blank">35344524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32756879">
<a name="32756879"></a>Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium. <i>J Infect Dis</i>. 2020;222(suppl 3):S175-S198. doi:10.1093/infdis/jiaa394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32756879/pubmed" id="32756879" target="_blank">32756879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27185799">
<a name="27185799"></a>Kovanda LL, Desai AV, Lu Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). <i>Antimicrob Agents Chemother</i>. 2016;60(8):4568-4576. doi:10.1128/AAC.00514-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/27185799/pubmed" id="27185799" target="_blank">27185799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427296">
<a name="31427296"></a>Lahmer T, Batres Baires G, Heilmaier M, et al. Influence of sustained low-efficiency dialysis treatment on isavuconazole plasma levels in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2019;63(11):e01162-19. doi:10.1128/AAC.01162-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/31427296/pubmed" id="31427296" target="_blank">31427296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26684607">
<a name="26684607"></a>Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i>. 2016;387(10020):760-769. doi:10.1016/S0140-6736(15)01159-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/26684607/pubmed" id="26684607" target="_blank">26684607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26969258">
<a name="26969258"></a>Marty FM, Ostrosky-Zeichner L, Cornely OA, et al; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infect Dis</i>. 2016;16(7):828-837. doi:10.1016/S1473-3099(16)00071-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/26969258/pubmed" id="26969258" target="_blank">26969258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29725999">
<a name="29725999"></a>McCarthy MW, Moriyama B, Petraitiene R, Walsh TJ, Petraitis V. Clinical pharmacokinetics and pharmacodynamics of isavuconazole. <i>Clin Pharmacokinet</i>. 2018;57(12):1483-1491. doi:10.1007/s40262-018-0673-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/29725999/pubmed" id="29725999" target="_blank">29725999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37459118">
<a name="37459118"></a>McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium. <i>Pharmacotherapy</i>. 2023;43(10):1043-1050. doi:10.1002/phar.2850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/37459118/pubmed" id="37459118" target="_blank">37459118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32710097">
<a name="32710097"></a>McCreary EK, Nguyen MH, Davis MR, et al. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>J Antimicrob Chemother</i>. Published online July 25, 2020. doi:10.1093/jac/dkaa274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32710097/pubmed" id="32710097" target="_blank">32710097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24403304">
<a name="24403304"></a>Peixoto D, Gagne LS, Hammond SP, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. <i>J Clin Microbiol</i>. 2014; 52(3):1016-1019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/24403304/pubmed" id="24403304" target="_blank">24403304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36836325">
<a name="36836325"></a>Perez L, Corne P, Pasquier G, et al. Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses. <i>J Fungi (Basel)</i>. 2023;9(2):211. doi:10.3390/jof9020211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/36836325/pubmed" id="36836325" target="_blank">36836325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33922419">
<a name="33922419"></a>Risum M, Vestergaard MB, Weinreich UM, Helleberg M, Vissing NH, Jørgensen R. Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole. <i>Antibiotics (Basel)</i>. 2021;10(5):487. doi:10.3390/antibiotics10050487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/33922419/pubmed" id="33922419" target="_blank">33922419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32218096">
<a name="32218096"></a>Ross JA, Karras NA, Tegtmeier B, et al. Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience. <i>J Pediatr Hematol Oncol</i>. 2020;42(4):261-265. doi:10.1097/MPH.0000000000001787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32218096/pubmed" id="32218096" target="_blank">32218096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33583766">
<a name="33583766"></a>Salas MQ, Mussetti A, Muñóz C, et al. Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: a single-center experience. <i>Hematol Transfus Cell Ther</i>. 2021:S2531-1379(21)00024-9. doi:10.1016/j.htct.2021.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/33583766/pubmed" id="33583766" target="_blank">33583766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19667286">
<a name="19667286"></a>Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. <i>Antimicrob Agents Chemother</i>. 2009;53(11):4885-4890. doi:10.1128/AAC.00319-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/19667286/pubmed" id="19667286" target="_blank">19667286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259. doi:10.1097/PCC.0b013e31819a383c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33247433">
<a name="33247433"></a>Spivey J, Wrenn R, Liu B, Maziarz E, Kram B. Characterization of isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: a case series. <i>J Clin Pharm Ther</i>. 2021;46(2):528-531. doi:10.1111/jcpt.13317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/33247433/pubmed" id="33247433" target="_blank">33247433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28271239">
<a name="28271239"></a>Townsend RW, Akhtar S, Alcorn H, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. <i>Eur J Clin Pharmacol</i>. 2017;73(6):669-678. doi:10.1007/s00228-017-2213-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/28271239/pubmed" id="28271239" target="_blank">28271239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28750160">
<a name="28750160"></a>Townsend R, Kato K, Hale C, et al. Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of <sup>14</sup> C-labeled isavuconazonium sulfate in healthy male volunteers. <i>Clin Pharmacol Drug Dev</i>. 2018;7(2):207-216. doi:10.1002/cpdd.376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/28750160/pubmed" id="28750160" target="_blank">28750160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 1, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated April 12, 2022. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25561337">
<a name="25561337"></a>Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. <i>Antimicrob Agents Chemother.</i> 2015;59(3):1671-1679. doi:10.1128/AAC.04586-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/25561337/pubmed" id="25561337" target="_blank">25561337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32580296">
<a name="32580296"></a>Zurl C, Waller M, Schwameis F, et al. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations. <i>J Fungi (Basel)</i>. 2020;6(2):90. doi:10.3390/jof6020090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isavuconazole-isavuconazonium-sulfate-pediatric-drug-information/abstract-text/32580296/pubmed" id="32580296" target="_blank">32580296</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139000 Version 79.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
